Marksans Pharma Ltd
MARKSANSMarksans Pharma Ltd
MARKSANS
Price Chart
Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 24.26 | 4.09 | 0.31% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.48 | 5.11 | 0.70% |
Forecast & Ratings
Detailed ForecastPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 800.03 | 902.20 | 774.18 | 921.16 | 1,004.69 | 1,134.54 | 1,382.87 | 1,532.69 | 1,911.45 | 2,054.83 | ||||||||||
Raw Materials | 446.74 | 504.85 | 506.68 | 502.58 | 517.91 | 514.88 | 731.33 | 703.92 | 927.75 | 1,594.98 | ||||||||||
| Power & Fuel Cost | 9.72 | 12.58 | 12.97 | 11.55 | 13.99 | 14.00 | 16.42 | 18.59 | 24.50 | |||||||||||
| Employee Cost | 72.61 | 122.42 | 149.70 | 147.75 | 159.07 | 168.42 | 197.32 | 220.30 | 239.37 | |||||||||||
| Selling & Administrative Expenses | 49.82 | 65.78 | 65.18 | 88.83 | 109.58 | 120.38 | 154.55 | 148.41 | 144.74 | |||||||||||
| Operating & Other expenses | 33.08 | 51.43 | -12.12 | 83.60 | 67.38 | 124.28 | -63.05 | 140.74 | 176.46 | |||||||||||
EBITDA | 188.06 | 145.14 | 51.77 | 86.85 | 136.76 | 192.58 | 346.30 | 300.73 | 398.63 | 459.85 | ||||||||||
| Depreciation/Amortization | 16.13 | 28.13 | 30.09 | 26.84 | 22.80 | 26.66 | 36.15 | 44.78 | 51.85 | 57.89 | ||||||||||
| PBIT | 171.93 | 117.01 | 21.68 | 60.01 | 113.96 | 165.92 | 310.15 | 255.95 | 346.78 | 401.96 | ||||||||||
| Interest & Other Items | 16.05 | 10.16 | 6.78 | 10.22 | 9.66 | 8.75 | 7.99 | 8.45 | 9.13 | 8.00 | ||||||||||
| PBT | 155.88 | 106.85 | 14.90 | 49.79 | 104.30 | 157.17 | 302.16 | 247.50 | 337.65 | 393.96 | ||||||||||
| Taxes & Other Items | 46.49 | 28.33 | 6.06 | 16.86 | 27.84 | 36.42 | 66.22 | 62.95 | 71.34 | 96.45 | ||||||||||
| Net Income | 109.39 | 78.52 | 8.84 | 32.93 | 76.46 | 120.75 | 235.94 | 184.55 | 266.31 | 297.51 | ||||||||||
| EPS | 2.75 | 1.92 | 0.22 | 0.80 | 1.87 | 2.95 | 5.76 | 4.51 | 6.18 | 6.57 | ||||||||||
| DPS | 0.12 | 0.41 | 0.05 | 0.05 | 0.05 | 0.10 | 0.25 | 0.25 | 0.50 | 0.50 | ||||||||||
| Payout ratio | 0.04 | 0.21 | 0.23 | 0.06 | 0.03 | 0.03 | 0.04 | 0.06 | 0.08 | 0.08 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Marksans Pharma Ltd | 27.10 | 4.09 | 0.31% |
| Sun Pharmaceutical Industries Ltd | 35.09 | 5.01 | 0.93% |
| Cipla Ltd | 35.23 | 4.16 | 0.69% |
| Dr Reddy's Laboratories Ltd | 21.37 | 4.14 | 0.69% |
Price Comparison
Compare MARKSANS with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Jan 2023
Mar 2023
Jun 2023
Sep 2023
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Marksans Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.9139% | Percentage of the fund’s portfolio invested in the stock 1.88% | Change in the portfolio weight of the stock over the last 3 months 0.19% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 9/125 (+4) |
UTI Aggressive Hybrid Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4791% | Percentage of the fund’s portfolio invested in the stock 0.70% | Change in the portfolio weight of the stock over the last 3 months 0.70% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 77/115 (+29) |
UTI Large & Mid Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.2496% | Percentage of the fund’s portfolio invested in the stock 0.82% | Change in the portfolio weight of the stock over the last 3 months 0.82% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 57/70 (+10) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
MARKSANS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.31%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.06 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJun 7, 2023
Dividend/Share
₹0.50
Ex DateEx Date
Jun 7, 2023
Cash Dividend
Ex DateEx DateAug 19, 2022
Dividend/Share
₹0.25
Ex DateEx Date
Aug 19, 2022
Cash Dividend
Ex DateEx DateSep 15, 2021
Dividend/Share
₹0.25
Ex DateEx Date
Sep 15, 2021
Cash Dividend
Ex DateEx DateSep 22, 2020
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2020
Cash Dividend
Ex DateEx DateSep 19, 2019
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2019
News & Opinions
News Video
Top Stocks In Focus Today | Granules India, Birla Soft, Marksans Pharma | Dhwani Patel
1 month ago•ET NOW
Marksans Pharma Consolidated June 2023 Net Sales at Rs 500.03 crore, up 15.28% Y-o-Y
3 months ago•Moneycontrol
Marksans Pharma shares rally 9% on FDA nod to pain relief tablet
4 months ago•Moneycontrol
Tata Power, Marksans Pharma, Uniparts India shares to turn ex-dividend today
6 months ago•Business Today
Stocks to Watch today | Tuesday, June 7: Adani Green, Mazagon Dock, Torrent Power | Business Standard
6 months ago•Business Standard
Marksans Pharma Consolidated March 2023 Net Sales at Rs 485.98 crore, up 16.25% Y-o-Y
6 months ago•Moneycontrol
Marksans Pharma completes the acquisition from Tevapharm India
7 months ago•Free Press Journal
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 15.72%, vs industry avg of 8.45%
Increasing Market Share
Over the last 5 years, market share increased from 0.45% to 0.6%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 51.9%, vs industry avg of 9.82%